Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Eskens FA, et al. Among authors: steeghs n. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636022 Clinical Trial.
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ, Samsom KG, Snaebjornsson P, Battaglia T, Bosch LJW, Lalezari F, Priestley P, Shale C, van den Broek AJ, Jacobs N, Roepman P, van der Hoeven JJM, Steeghs N, Vollebergh MA, Marchetti S, Cuppen E, Meijer GA, Voest EE, Monkhorst K. Schipper LJ, et al. Among authors: steeghs n. ESMO Open. 2022 Dec;7(6):100611. doi: 10.1016/j.esmoop.2022.100611. Epub 2022 Dec 1. ESMO Open. 2022. PMID: 36463731 Free PMC article.
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S. Hamberg P, et al. Among authors: steeghs n. Br J Cancer. 2010 Jun 8;102(12):1699-706. doi: 10.1038/sj.bjc.6605696. Epub 2010 May 18. Br J Cancer. 2010. PMID: 20485286 Free PMC article. Clinical Trial.
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Lankheet NA, et al. Among authors: steeghs n. Br J Cancer. 2014 May 13;110(10):2441-9. doi: 10.1038/bjc.2014.194. Epub 2014 Apr 15. Br J Cancer. 2014. PMID: 24736581 Free PMC article. Clinical Trial.
214 results